San Francisco, CA (UroToday.com) — Telix announces that a first patient has been dosed in a Phase I study of TLX250-CDx in patients with bladder cancer.
Telix is pleased to announce that a first patient has been dosed in a Phase I study of TLX250-CDx (89Zr-DFO-girentuximab) in patients with urothelial carcinoma or bladder cancer at Fiona Stanley Hospital in Perth, Western Australia.